Effect of L-Arginine on the Serum Level of Advanced Glycation End Products in Patients with Post Infarction Chronic Heart Failure
DOI:
https://doi.org/10.6000/1929-5634.2017.06.02.1Keywords:
Heart failure with preserved ejection fraction, advanced glycated end products, endothelialdys function, myocardialinfarction, L-ArginineAbstract
Post-infarction heart failure with preserved ejection fraction (HFpEF) determines a great morbidity and mortality, and given the physiopathology implications of advanced glycation end products (AGEs) in the genesis of myocardial dysfunction. As known endothelial dysfunction is an independent predictor for cardiovascular disease. L-Arginine is the amino acid with potential to improve endothelial function which leading to prevention and treatment of cardiovascular diseases, and we think that L-Arginine may decrease the serum AGEs. We aimed to estimate the value of AGEs in post-infarction HFpEF patients, and detect the effect of L-Arginine on the serum level of AGEs in post-infarction HFpEF pts. all individuals (25) included aged 40 to 80 years, 20(80%) males and 5(20%) females were diagnosed with (HFpEF) according to ESC guidelines (2012), and their functional class according to NYHA classification for HF. 20(80%) patients of them have myocardial infarction in anamnesis. 1st group:13 patients with HFpEF and history of myocardial infarction with L-Arginine added to their standard treatment. 2nd group:7 patients with HFpEF and history of myocardial infarction with standard treatment (without L-Arginine). Comparsion group: 5 patients with HFpEF with standard treatment. We prescribed L. Arginine aspartate (Tivortin 4.2gm) intravenously once daily for 10 days for all 1st group patients. The levels of total cholesterol, triglycerides, glucose, white blood cells, erythrocyte sedimentation rate and AGEs serum level were deterimined. AGEs serum level increased markedly increased in middle-age pts with post infarction HFpEF. Inclusion of L-arginine aspartate in complex of treatment for post infarction HFpEF contributed to the significant decrease AGEs level in >60 years old patients.
References
Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003; 41(5 Suppl): 11-17. https://doi.org/10.1016/S0272-6386(03)00372-X
Mann M, Jensen ON. Proteomic analysis of post-translational modifications. Nat Biotechnol 2003; 21: 255-261. https://doi.org/10.1038/nbt0303-255
Gillery P, Jaisson S. Usefulness of non-enzymatic post-translational modification derived products (PTMDPs) as biomarkers of chronic diseases. J Proteomics 2013; 92: 228-238. https://doi.org/10.1016/j.jprot.2013.02.015
Gillery P, Jaisson S. Post-translational modification derived products (PTMDPs): toxins in chronic diseases? Clin Chem Lab Med 2014; 52: 33-38. https://doi.org/10.1515/cclm-2012-0880
Maillard L-C. Action des acides amines sur les sucres: formation des melanoidines par voie methodique. C R Seances Acad Sci III 1912; 154: 66-68.
Rabbani N, Sebekova K, Sebekova K Jr., et al. Accumulation of free adduct glycation, oxidation, and nitration products follows acute loss of renal function. Kidney Int 2007; 72: 1113-1121. https://doi.org/10.1038/sj.ki.5002513
Sadik NA, Mohamed WA, Ahmed MI. The association of receptor of advanced glycated end products and inflammatory mediators contributes to endothelial dysfunction in a prospective study of acute kidney injury patients with sepsis. Mol Cell Biochem 2012; 359: 73-81. https://doi.org/10.1007/s11010-011-1001-4
Tarng DC, Huang TP, Wei YH, et al. 8-hydroxy-20-deoxyguanosine of leukocyte DNA as a marker of oxidative stress in chronic hemodialysis patients. Am J Kidney Dis 2000; 36: 934-944. https://doi.org/10.1053/ajkd.2000.19086
Simm A. Protein glycation during aging and in cardiovascular disease. J Proteomics 2013; 92: 248-259. https://doi.org/10.1016/j.jprot.2013.05.012
Sell DR, Monnier VM. End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest 1990; 85: 380-384. https://doi.org/10.1172/JCI114449
Smit AJ, Hartog JW, Voors AA, et al. Advanced glycation endproducts in chronic heart failure. Ann N Y Acad Sci 2008; 1126: 225-30. https://doi.org/10.1196/annals.1433.038
Dunlay SM, Redfield MM, Weston SA, et al. Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol 2009; 54: 1695-702. https://doi.org/10.1016/j.jacc.2009.08.019
Hartog JW, Voors AA, Bakker SJ, et al. Advanced glycation endproducts (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail 2007; 9: 1146-55. https://doi.org/10.1016/j.ejheart.2007.09.009
Miyata T, Sugiyama S, Saito A, et al. Reactive carbonyl compounds related uremic toxicity ("carbonyl stress"). Kidney Int Suppl 2001; 78: S25-31. https://doi.org/10.1046/j.1523-1755.2001.59780025.x
Raposeiras-Roubín S, Rodiño-Janeiro BK, Grigorian-Shamagian L, et al. Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: new roles for soluble RAGE. Eur J Heart Fail 2010; 12: 1092-100. https://doi.org/10.1093/eurjhf/hfq117
Lindsey JB, de Lemos JA, Cipollone F, et al. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care 2009; 32: 1218-20. https://doi.org/10.2337/dc09-0053
Falcone C, Emanuele E, D'Angelo A, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005; 25: 1032-7. https://doi.org/10.1161/01.ATV.0000160342.20342.00
Ramasamy R, Yan SF, Schmidt AM. Advanced glycation endproducts: from precursors to RAGE: round and round we go. Amino Acids 2010: 19.
Hartog JW, Voors AA, Schalkwijk CG, et al. Clinical and prognostic value of advanced glycation end-products in chronic heart failure. Eur Heart J 2007; 28: 2879-85. https://doi.org/10.1093/eurheartj/ehm486
Koyama Y, Takeishi Y, Arimoto T, et al. High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J Card Fail 2007; 13: 199-206. https://doi.org/10.1016/j.cardfail.2006.11.009
Raposeiras-Roubín S, Rodiño-Janeiro BK, Grigorian-Shamagian L, et al. Relation of soluble receptor for advanced glycation end products to predict mortality in patients with chronic heart failure independently of Seattle Heart Failure Score. Am J Cardiol 2010; 107: 938-44. https://doi.org/10.1016/j.amjcard.2010.11.011
Macchia A, Levantesi G, Marfisi RM, Franzosi MG, Maggioni AP, Nicolosi GL, Schweiger C, Tavazzi L, Tognoni G, Valagussa F, et al. Determinants of lateonset heart failure in myocardial infarction survivors: GISSI Prevenzione trial results. Rev Esp Cardiol 2005; 58(11): 1266-1272. https://doi.org/10.1157/13080953
Gajarsa JJ, Kloner RA. Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev 2011; 16(1): 13-21. https://doi.org/10.1007/s10741-010-9181-7
Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000; 35(3): 569-582. https://doi.org/10.1016/S0735-1097(99)00630-0
Roig Minguell E. Clinical use of markers of neurohormonal activation in heart failure. Rev Esp Cardiol 2004; 57(4): 347-356. https://doi.org/10.1016/S0300-8932(04)77113-4
Dominguez Rodriguez A, Abreu Gonzalez P, Garcia Gonzalez MJ, Ferrer Hita J. Association between serum interleukin 10 level and development of heart failure in acute myocardial infarction patients treated by primary angioplasty. Rev Esp Cardiol 2005; 58(6): 626-630. https://doi.org/10.1016/s1885-5857(06)60248-x
Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, Kislinger T, Stern DM, Schmidt AM, De Caterina R. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002; 105(7): 816-822. https://doi.org/10.1161/hc0702.104183
Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107(9): 1058-1070. https://doi.org/10.1161/CIRCRESAHA.110.223545
Hartog JW, Voors AA, Bakker SJ, Smit AJ, van Veldhuisen DJ. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail 2007; 9(12): 1146-1155. https://doi.org/10.1016/j.ejheart.2007.09.009
Kioifman B, Wollam Y, Bogomolny N, et al. Improved cardiac performance by intravenous infusion of L-arginine in patients with moderate congestive cardiac failure. J Am Coll Cardiol 1995; 26: 1251-1256. https://doi.org/10.1016/0735-1097(95)00318-5
ESC Guidelines for the diagnosis and treatment The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC, European Heart Journal. https://doi.org/10.1093/eurheartj/ehs104
Soro-Paavonen A, Zhang WZ, Venardos K, Coughlan MT, Harris E, Tong DC, et al. Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase. J Hypertens 2010, 28(4): 780-788. https://doi.org/10.1097/HJH.0b013e328335043e
Wang J, Liu H, Chen B, Li Q, Huang X, Wang L, Guo X, Huang Q. RhoA/ ROCK-dependent moesin phosphorylation regulates AGE-induced endothelial cellular response. Cardiovasc Diabetol 2012; 11: 7. https://doi.org/10.1186/1475-2840-11-7
Li H, Zhang X, Guan X, Cui X, Wang Y, Chu H, Cheng M. Advanced glycation end products impair the migration, adhesion and secretion potentials of late endothelial progenitor cells. Cardiovasc Diabetol 2012; 11(1): 46. https://doi.org/10.1186/1475-2840-11-46
Yang K, Wang XQ, He YS, Lu L, Chen QJ, Liu J, Shen WF. Advanced glycation end products induce chemokine/cytokine production via activation of p38 pathway and inhibit proliferation and migration of bone marrow mesenchymal stem cells. Cardiovasc Diabetol 2010; 9: 66. https://doi.org/10.1186/1475-2840-9-66
Kamioka M, Ishibashi T, Sugimoto K, Uekita H, Nagai R, Sakamoto N, et al. Blockade of renin-angiotensin system attenuates advanced glycation end products-mediated signalling pathways. J Atheroscler Thromb 2010; 17(6): 590-600. https://doi.org/10.5551/jat.3624
Yamagishi S, Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, Fukami K, Okuda S, Imaizumi T. Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvasc Res 2008; 75(1): 130-134. https://doi.org/10.1016/j.mvr.2007.05.001
Koka V, Wang W, Huang XR, Kim-Mitsuyama S, Truong LD, Lan HY. Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications. Circulation 2006; 113(10): 1353-1360. https://doi.org/10.1161/CIRCULATIONAHA.105.575589
Hartog JW, Willemsen S, van Veldhuisen DJ, Posma JL, van Wijk LM, Hummel YM, Hillege HL, Voors AA. Effects of alagebrium, an advanced glycation endproduct breaker, on
exercise tolerance and cardiac function in patients with chronic heart failure. Eur J Heart Fail 2011; 13(8): 899-908. https://doi.org/10.1093/eurjhf/hfr067
Norton GR, Candy G, Woodiwiss AJ. Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation 1996; 93(10): 1905-1912. https://doi.org/10.1161/01.CIR.93.10.1905
Liu J, Masurekar MR, Vatner DE, Jyothirmayi GN, Regan TJ, Vatner SF, Meggs LG, Malhotra A. Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am J Physiol Heart Circ Physiol 2003; 285(6): H2587-2591. https://doi.org/10.1152/ajpheart.00516.2003
Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 2005; 11(3): 191-195. https://doi.org/10.1016/j.cardfail.2004.09.010
Thohan V, Koemer MM, Pratt CM, Torre GA. Improvements in diastolic function amond patients with advenced systolic heart failure utilizing alagebrium (an oral advanced glycation end-product cross-link breaker). Circulation 2005; 112(Suppl 2): U620. 2647.
Downloads
Published
How to Cite
Issue
Section
License
Policy for Journals/Articles with Open Access
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work
Policy for Journals / Manuscript with Paid Access
Authors who publish with this journal agree to the following terms:
- Publisher retain copyright .
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .
